| Next generation of immune checkpoint therapy in cancer: new developments and challenges JA Marin-Acevedo, B Dholaria, AE Soyano, KL Knutson, S Chumsri, ... Journal of hematology & oncology 11, 1-20, 2018 | 765 | 2018 |
| Next generation of immune checkpoint inhibitors and beyond JA Marin-Acevedo, EMO Kimbrough, Y Lou Journal of hematology & oncology 14, 1-29, 2021 | 458 | 2021 |
| Cancer immunotherapy beyond immune checkpoint inhibitors JA Marin-Acevedo, AE Soyano, B Dholaria, KL Knutson, Y Lou Journal of hematology & oncology 11 (1), 8, 2018 | 214 | 2018 |
| Immunotherapy for advanced non–small cell lung cancer: a decade of progress MD Shields, JA Marin-Acevedo, B Pellini American Society of Clinical Oncology Educational Book 41, e105-e127, 2021 | 132 | 2021 |
| Immune checkpoint inhibitor toxicities JA Marin-Acevedo, RM Chirila, RS Dronca Mayo Clinic Proceedings 94 (7), 1321-1329, 2019 | 129 | 2019 |
| Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies AE Soyano, B Dholaria, JA Marin-Acevedo, N Diehl, D Hodge, Y Luo, ... Journal for immunotherapy of cancer 6 (1), 129, 2018 | 111 | 2018 |
| Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia V Kumar, S Ailawadhi, L Bojanini, A Mehta, S Biswas, T Sher, V Roy, ... Blood cancer journal 9 (10), 75, 2019 | 61 | 2019 |
| Immunotherapy‐induced colitis: An emerging problem for the hospitalist JA Marin‐Acevedo, DM Harris, MC Burton Journal of hospital medicine 13 (6), 413-418, 2018 | 31 | 2018 |
| Immunotherapies targeting stimulatory pathways and beyond JA Marin-Acevedo, EMO Kimbrough, R Manochakian, Y Zhao, Y Lou Journal of hematology & oncology 14 (1), 78, 2021 | 27 | 2021 |
| Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy Y Lou, JA Marin-Acevedo, P Vishnu, R Manochakian, B Dholaria, ... Immunotherapy 11 (7), 577-584, 2019 | 19 | 2019 |
| Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy JJ Failing, OA Dudek, JA Marin Acevedo, RM Chirila, H Dong, ... Future Oncology 15 (22), 2645-2656, 2019 | 14 | 2019 |
| Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data JA Marin-Acevedo, B Pellini, EMO Kimbrough, JK Hicks, A Chiappori Cancers 15 (3), 629, 2023 | 12 | 2023 |
| Cardiac sarcoidosis: case presentation and review of the literature N Chamorro-Pareja, JA Marin-Acevedo, RM Chirilă Romanian Journal of Internal Medicine 57 (1), 7-13, 2019 | 12 | 2019 |
| Non-atherosclerotic aortic mural thrombus: a rare source of embolism JA Marin-Acevedo, AH Koop, JL Diaz-Gomez, PK Guru Case Reports 2017, bcr-2017-220592, 2017 | 12 | 2017 |
| Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer B Schlick, MD Shields, JA Marin-Acevedo, I Patel, B Pellini Current Treatment Options in Oncology 23 (8), 1104-1120, 2022 | 11 | 2022 |
| Association of CDKN2A gene alteration with high expression of PD-L1. Y Zhang, JA Marin-Acevedo, AG Azzouqa, R Manochakian, Y Lou Journal of Clinical Oncology 36 (15_suppl), 9102-9102, 2018 | 8 | 2018 |
| Efficacy of cetuximab after immunotherapy (IO) in advanced cutaneous squamous cell carcinoma (CSCC). JA Marin-Acevedo, B Withycombe, Y Kim, Z Eroglu, J Markowitz, AS Brohl, ... Journal of Clinical Oncology 39 (15_suppl), 9562-9562, 2021 | 7 | 2021 |
| Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma JA Marin-Acevedo, BM Withycombe, Y Kim, AS Brohl, Z Eroglu, ... Cancers 15 (12), 3180, 2023 | 5 | 2023 |
| Ocular tuberculosis JA Marin-Acevedo, RM Chirila, JB Cowart Journal of General Internal Medicine 34, 2288-2289, 2019 | 5 | 2019 |
| Baseline peripheral blood biomarkers associated with clinical outcome of advanced lung cancer in patients treated with anti-PD-1 antibody. AE Soyano, BR Dholaria, JA Marin-Acevedo, NN Diehl, D Hodge, Y Lou Journal of Clinical Oncology 35 (15_suppl), e20599-e20599, 2017 | 5 | 2017 |
Bhagirathbhai Dholaria, MDVanderbilt university medical center在 vumc.org 的电子邮件经过验证
